On December 13, 2019, Cleveland BioLabs, Inc. appointed Christopher Zosh, the Company's current Vice President of Finance, to serve as the Company's interim principal executive officer, principal financial officer and principal accounting officer while the Company's board of directors continues its search for a permanent Chief Executive Officer. Mr. Zosh succeeds Yakov Kogan, whose resignation as Chief Executive Officer became effect on December 13, 2019. Christopher Zosh, 44, has served as Vice President of Finance of the Company since January 1, 2019.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0007 USD | 0.00% | 0.00% | -99.98% |
2023 | Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs. | CI |
2023 | Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index | CI |
1st Jan change | Capi. | |
---|---|---|
+0.69% | 42.86B | |
+12.32% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+6.19% | 25.15B | |
-23.56% | 18.63B | |
+27.60% | 12.37B | |
-3.30% | 11.92B | |
+6.87% | 11.21B |
- Stock Market
- Equities
- STAB Stock
- STAB Stock
- News Statera Biopharma, Inc.
- Cleveland Biolabs, Inc. Announces Executive Changes